The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.
Maasch C, Vater A, Buchner K, Purschke WG, Eulberg D, Vonhoff S, Klussmann S.
Polyethylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.
J. Biol. Chem. 2010, Vol. 285(51), 40012-8.
view PubMed abstract on ncbi.nlm.nih.gov
Sayyed, S. G., Gaikwad, A. B., Lichtnekert, J., Kulkarni, O. P., Eulberg, D., Klussmann, S., Tikoo, K. & Anders, H.-J.
Progessive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.
Nephrol. Dial. Transplant. 2010, Vol. 25(6), 1811-7.
view PubMed abstract on ncbi.nlm.nih.gov
Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.
Diabetologia 2009, Vol. 52(11), 2445-2454.
view PubMed abstract on ncbi.nlm.nih.gov
Schlesinger, J., Fischer, C., Koezle, I., Vonhoff, S., Klussmann, S., Bergmann, R., Pietzsch, H.-J. & Steinbach, J.
Radiosynthesis of new [90Y]-DOTA-based maleimide reagents suitable for the prelabeling of thiol-bearing L-oligonucleotides and peptides.
Bioconj. Chem. 2009, Vol. 20(7), 1340-1348.
view PubMed abstract on ncbi.nlm.nih.gov
Clauss, S., Gross, O., Kulkarni, O., Avila-Ferrufino, A., Radomska, E., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy.
J. Pathol. 2009, Vol. 218(1), 40-47.
view PubMed abstract on ncbi.nlm.nih.gov
Kulkarni, O., Eulberg, D., Selve, N., Zöllner, S., Allam, R., Pawar, R. D., Pfeiffer, S., Segerer, S., Klussmann, S., & Anders, H.-J.
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
J. Pharmacol. Exp. Ther. 2009, Vol. 328(2), 371-377.
view PubMed abstract on ncbi.nlm.nih.gov